Erlotinib in Treating Patients With Stage III or Stage IV Pancreatic Cancer

Summary

RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well erlotinib works in treating patients with stage III or stage IV pancreatic cancer.

Timeline

Start

2007-01

Primary completion

2009-01

Completion

2010-09

Outcome

Outcome not reported

Stopped: “This study was terminated earlier due to a phase III study that showed this drug inferior to sorafenib”

Drugs

Indications